
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
A randomized, placebo-controlled, double-blind clinical study with metronidazole in patients with mild to moderate seborrheic dermatitis found the drug seemed to lack effectiveness.






